

## **ALEXANDER MAUSKOP, MD**

Dr. Alexander Mauskop is the founder and director of the New York Headache Center. He is board-certified in Neurology and Headache Medicine and is an Associate Professor of Clinical Neurology at the State University of New York, Downstate Medical Center. Dr. Mauskop has conducted and published original research in the field of headaches, particularly on the role of magnesium in headaches. He has authored three books and multiple research articles. He serves as a reviewer for several medical journals, including *New England Journal of Medicine*, *Neurology*, *Headache*, and *Cephalalgia*.

Throughout his career Dr. Mauskop has been committed to educating physicians about headaches. Over 200 doctors from all over the world have visited the New York Headache Center to receive advanced training. For the past 21 years Dr. Mauskop has led an annual educational symposium on headaches. He has given hundreds of lectures, including grand rounds and lectures at institutions such as Cornell, Harvard, Columbia, NYU and Dartmouth Medical Schools, and Mayo and Cleveland Clinics. He has been invited to speak at the meetings of the American Academy of Neurology, American Headache Society and International Headache Society.

Dr. Mauskop has appeared on local and national television and radio programs, including Tom Brokaw's News Hour, ABC Evening News, Extra, Fox News, and PBS Special. A feature article on his work appeared in *Vogue* magazine and he has been interviewed for *O, the Oprah Magazine*, *USA Today*, *San Francisco Examiner*, *Cosmopolitan*, *Bloomberg News* and many other national publications.

### **CURRENT POSITIONS**

#### **ASSOCIATE PROFESSOR OF CLINICAL NEUROLOGY**

State University of New York, Downstate Medical Center, Brooklyn, NY

**ATTENDING NEUROLOGIST**, Beth Israel Hospital, New York, NY

**DIRECTOR, New York Headache Center**

30 East 76<sup>th</sup> Street, New York, NY 10021, (212) 794-3550

E-mail: DrMauskop@NYHeadache.com

**DIRECTOR, New York Headache Foundation**

**REVIEWER**, *New England Journal of Medicine*, *Neurology*, *Cephalalgia*, *Headache*, *The Journal of Headache and Pain*, *Functional Neurology*, *Journal of Pain and Symptom Management*, *The Clinical Journal of Pain*, *Expert Review of Neurotherapeutics*, *Disease Management & Health Outcomes*, *Clinical Drug Investigation*, *Alternative Therapies in Health and Medicine*.

**DIRECTOR**, Annual Symposium on the Treatment of Headaches & Facial Pain (1989-present)

**MEMBER**, Editorial Board, *Headache Research and Treatment*, *Pain Medicine News*

**MEMBER**, Board of Trustees, Anne Frank Center USA.

## **EDUCATION & TRAINING**

7/1/84 - 3/31/86      **PAIN FELLOWSHIP**  
 Memorial Sloan-Kettering Cancer Center, New York, NY

7/1/81 - 6/30/84      **NEUROLOGY RESIDENCY**  
 SUNY - Downstate Medical Center, Brooklyn, NY

4/14/80 - 6/30/81      **MEDICAL INTERNSHIP**  
 Brookdale Hospital, Brooklyn, NY

9/1/73 - 6/14/79      **MEDICAL SCHOOL**  
 Uzhgorod State University, Uzhgorod, USSR

## **BOARD CERTIFICATIONS**

### **DIPLOMATE**

**American Board of Psychiatry and Neurology (Neurology) 1987**  
**Subspecialty certification in Headache Medicine 2006**  
**American Board of Pain Medicine 1995**

### **PAST POSITIONS**

**CHAIRMAN**, Scientific Program Committee, Eastern Pain Association 1993-1994

**PRESIDENT**, Eastern Pain Association, 1997-1998

**MEMBER**, Task Force on Special Pain Problems Related to Women International Association for the Study of Pain, 1990-1993

**CHAIR**, Headache Section, American Society for Clinical Pharmacology & Therapeutics, 1996-1998

**CHAIRMAN**, CME Committee, Medical Society of County of Kings, 1996-1997

**MEMBER**, Task Force on Chronic Pain - Headache, Agency for Health Care Policy & Research (AHCPR)

**CHAIRMAN**, Board of Directors, Eastern Pain Association. 1999-2002.

**MEMBER**, Editorial Board, *Headache* 2001-2003.

**CHAIRMAN**, Complementary and Alternative Medicine Section, American Headache Society (1999-2004)

**CHAIR, Analgesiology & Headache Section**, American Society for Clinical Pharmacology & Therapeutics (2002-2004)

### **GRANTS**

1984 - 1986      **National Research Service Award**  
 National Institutes of Health Grant CA-09461

1995      **National Headache Foundation Grant**  
 Magnesium Supplementation as a Potential Treatment of Headaches and Premenstrual Syndrome in Women

1998      **American Council for Headache Education Lecture Award**

*Alternative Treatments for Headache: The Scientific Basis*  
40<sup>th</sup> Annual Scientific Meeting of the American Association for the Study  
of Headache

**PROFESSIONAL LICENSES**      **To practice medicine in the State of New York**  
**To use acupuncture in an investigational capacity in the State of NY**

**PROFESSIONAL SOCIETIES**      **American Academy of Neurology (Fellow)**  
**New York Academy of Medicine (Fellow)**  
**International Association for the Study of Pain**  
**American Pain Society**  
**Eastern Pain Association**  
**American Headache Society**  
**International Headache Society**  
**Medical Society of the State of New York**  
**Medical Society of County of New York**

#### **ORIGINAL PUBLICATIONS**

1. Mauskop A, Wolintz AH, Valderrama R: **Subdural hematoma and cerebral ischemia; advantage of nuclear magnetic resonance imaging.** *J Clin NeuroOphthalmol* 4:251-253,1984.
2. Mauskop A: **A new headache type with specific EEG changes.** *Headache Quarterly.* 3(4):448-453,1992.
3. Mauskop A, Altura BT, Cracco RQ, Altura BM: **Deficiency in serum ionized Mg but not total Mg in patients with migraine. Possible role of  $ICa^{2+}/IMg^{2+}$  ratio.** *Headache* 33(3):135-138,1993.
4. Mauskop A, Altura BT, Cracco RQ, Altura BM: **Serum ionized magnesium levels in patients with tension-type headaches.** In: Olesen J and Schoenen J, eds. *Tension-type headache: classification, mechanisms and treatment.* New York: Raven Press, 1993.
5. Mauskop A, Altura BT, Cracco RQ, Altura BM: **Chronic daily headache - one disease or two? Diagnostic role of serum ionized magnesium.** *Cephalalgia* 1994; 14: 24-28.
6. Mauskop A, Altura BT, Cracco RQ, Altura BM: **Ionized Mg, total Mg and  $ICa^{2+}/IMg^{2+}$  ratios in patients with episodic and chronic cluster headaches.** *Headache Quarterly* 1994; 5(2A):156-158.
7. Altura BT, Burack JL, Cracco RQ, Galland L, Handwerker SM, Markell MS, Mauskop A, Memon ZS, Resnick LM, Zisbrod Z, Altura BM: **Clinical studies with the NOVA ISE for  $IMg^{2+}$ .** *Scan J Lab Clin Invest*; 1994;Suppl 21 7: 53-67.
8. Mauskop A, Altura BT, Cracco RQ, Altura BM: **Intravenous magnesium sulfate relieves cluster headaches in patients with low serum ionized magnesium levels.** *Headache* 1995;35:597-600.
9. Mauskop A, Altura BT, Cracco RQ, Altura BM: **Intravenous magnesium sulfate relieves acute migraine in patients with low serum ionized magnesium levels.** *Clinical Science* 1995;89:633-636.
10. A. Mauskop, BT Altura, RQ Cracco, BM Altura. **Intravenous magnesium sulfate rapidly alleviates headaches of various types.** *Headache* 1996; 36:154-160.

11. R. Michael Gallagher, for the Dihydroergotamine Working Group. **Acute treatment of migraine with dihydroergotamine nasal spray.** *Arch Neurol* 1996; 53:1285-1291.
12. Mauskop A, Altura BT, Cracco RQ, Altura BM: **Serum ionized magnesium levels as a biological marker in patients with headaches.** *Headache Quarterly*, 1996;7(2):142-144.
13. Mauskop A, Farkkila M, Hering-Hanit R, Rapoport A, Warner J. **Zolmitriptan is effective for the treatment of persistent and recurrent migraine headache.** *Curr Med Res Opin* 1999;15(4):282-289.
14. Tuchman M, Edvinsson L, Geraud G, Korczyn A, Mauskop A, Pfaffenrath V. **Zolmitriptan provides consistent migraine relief when used in the long-term.** *Curr Med Res Opin* 1999;15(4):272-281.
15. Mauskop A, Altura BT, Altura BM: **Serum ionized magnesium levels and serum ionized calcium/ionized magnesium ratios in women with menstrual migraine.** *Headache* 2002;42:242-248.
16. Lipton RB, Göbel H, Einhüpl KM, Wilks K, Mauskop A: **Petasites hybridus root (Butterbur) is an effective preventive treatment for migraine.** *Neurology* 2004;63:2240-2244.
17. Mauskop A. **Vagus Nerve Stimulation Relieves Chronic Refractory Migraine and Cluster Headaches.** *Cephalalgia* 2005;25:82-86.
18. Dodick DW, Mauskop A, Elkind AH, et al. **Botulinum Toxin Type A for the Prophylaxis of Chronic Daily Headache: Subgroup Analysis of Patients Not Receiving Other Prophylactic Medications: A Randomized Double-Blind, Placebo-Controlled Study.** *Headache* 2005;45:315-324.
19. Cady R, Martin V, Mauskop A, Rodgers A, Hustad CM, Ramsey, KE, Skobieranda F. **Efficacy of Rizatriptan, 10 mg Administered Early in a Migraine Attack.** *Headache* 2006;46(6) :914-924.
20. Rapoport A, Mauskop A, Diener H-C, Schwalen S, Pfeil J. **Long-term Migraine Prevention with Topiramate: Open-Label Extension of Pivotal Trials.** *Headache* 2006;46(7):1151-1160.
21. Smith T, Blumenthal H, Diamond M, Mauskop A, et al. **Sumatriptan/Naproxen Sodium for Migraine: Efficacy, Health Related Quality of Life, and Satisfaction Outcomes.** *Headache* 2007;47:683-692.
22. Cady R, Martin, V, Mauskop A, Rodgers A, et al. **Symptoms of cutaneous sensitivity pretreatment and posttreatment: results from the rizatriptan TAME studies.** *Cephalalgia*, 2007;27:1055-60.
23. Martin V, Cady R, Mauskop A et al. **Efficacy of Rizatriptan for Menstrual Migraine in an Early Intervention Model.** *Headache* 2008;48:226-235.
24. Chou R, Fanciullo GJ, Fine PG, Adler JA, Ballantyne JC, Davies, P, Donovan, MI, Fishbain, DA, Foley KM, Fudin J, Gilson AM, Kelter A, Mauskop A, et al. **Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain.** *The Journal of Pain* 2009;10(2):113-130.

## ABSTRACTS

1. Mauskop A, Coyle N, Maggard J, Foley KM: Continuous subcutaneous infusion of opiates in cancer patients with pain: safety and efficacy. *Amer. Soc. Clin. Onco.* 4:39, 1985.

2. Breitbart W, Loscalzo M, Mauskop A, Foley KM: Short-term group therapy for out-patients with chronic non-malignant pain. *Amer. Pain Soc.*,53, 1985.
3. Mauskop A, Coyle N, Inturrisi CE, Maggardj, Foley KM: **Continuous subcutaneous infusion (CSCI) of narcotic analgesics (NA) in cancer patients with pain.** *Amer. Pain Soc.*, 22, 1985.
4. Lowenthal DA, Scher H, Mauskop A, Foley KM: **Prospective evaluation of 35 patients with prostatic cancer (PC) with suspected epidural spinal cord metastases (ESCM).** *Amer. Soc. Clin. Onco.*, 1985.
5. Mauskop A, Coyle N, Maggard J, Foley KM: **Continuous subcutaneous infusion of narcotics in cancer patients with pain.** Proceedings of the Vth World Congress on Pain. Hamburg, West Germany, August 6,1987.
6. Mauskop A: **A possible new migraine syndrome.** (Abstract) *Neurology* Vol.40, 4(Suppl. 1):436.
7. Mauskop A, Altura BT, Cracco RQ, Altura BM: **Serum ionized magnesium levels during and between migraine attacks.** *Clinical Research* 40:657A, 1992.
8. Mauskop A, Altura BT, Cracco RQ, Altura BM: **The role of serum ionized magnesium in menstrual migraine.** Proceedings of the American Pain Society's Annual Meeting, San Diego, CA 1992.
9. Mauskop A, Altura BT, Cracco RQ, Altura BM: **Serum ionized magnesium and calcium in headache classification.** *Soc. Neurosci. Abstr.* 18(1):201, 1992.
10. Mauskop A, Altura BT, Cracco RQ, Altura BM: **Serum ionized magnesium (IMg<sup>2+</sup>) levels in patients (P) with episodic and chronic cluster headaches (CH).** *Clin Pharm Ther* 53(2):227, 1993.
11. Mauskop A, Altura BT, Cracco RQ, Altura BM: **The incidence of serum ionized magnesium deficiency in patients with an acute migraine headache is higher than in patients with an acute tension-type headache.** Proceedings of the 35th Annual Scientific Meeting of the American Association for the Study of Headache, June 1993.
12. Mauskop A, Altura BT, Cracco RQ, Altura BM: **Serum ionized magnesium (1mg<sup>2+</sup>) levels and ICa<sup>2+</sup>/IMg<sup>2+</sup> ratio as biological markers for certain headache types.** Proceedings of the Filth World Congress on Pain. Paris, France. August 22-27,1993.
13. Mauskop A, Altura BT, Cracco RQ, Altura BM: **Serum ionized magnesium (IMg<sup>2+</sup>) in classification of patients (P) with daily headaches (DH).** Proceedings of the VIth International Headache Congress. Paris, France. August 26-29,1993. *Cephalalgia* 1993;13:238.
14. Mauskop A, Altura BT, Cracco RQ, Altura BM: **Serum ionized magnesium deficiency is common in women with menstrual migraine.** *Neurology* 1994; 44 (4 suppl): 243S.
15. Mauskop A, Altura BT, Cracco RQ, Altura BM: **Treatment of cluster headaches with intravenous magnesium sulfate.** Proceedings of the 13th Annual Scientific Meeting of the American Pain Society, 1994.
16. Mauskop A, Altura BT, Cracco RQ, Altura BM: **Intravenous magnesium sulfate relieves cluster headaches in patients with low serum ionized magnesium levels.** *Clin Pharm Ther* 57(2):201, 1995.
17. Mauskop A, Altura BT, Cracco RQ, Altura BM: **Intravenous magnesium sulfate relieves acute migraine in patients with low serum ionized magnesium levels.** *Neurology* 1995; 45(suppl 4): A379.

18. Mauskop A, Altura BT, Cracco RQ, Altura BM: **Magnesium deficiency may predispose conversion of migraines into chronic daily headaches (transformed migraines) with loss of responsiveness to magnesium infusions.** *Clin Pharm Ther* 1996;59(2):196.
19. Mauskop A, Altura BT, Cracco RQ, Altura BM: **Intravenous magnesium for the prophylaxis of menstrual migraines.** *Cephalalgia* 1997;17(3):425.
20. Mauskop A, Altura BT, Cracco RQ, Altura BM: **An open trial of magnesium supplementation for the treatment of migraines and symptoms of premenstrual syndrome in premenopausal women. Effect on serum ionized Mg levels.** *Neurology* 1997;48:A261.
21. Mauskop A, **Long-term opioid maintenance in patients with headaches.** *Clin Pharm Ther* 1997;60(2):196.
22. Sawyer J, Spruce K, Mauskop A, Warner J. **Effective treatment of persistent or recurrent migraine headache with Zomig.** *European Journal of Neurology*. 1998;5(suppl 3):S54-55.
23. Mauskop A. **Botulinum toxin relieves myofascial neck and upper back pain.** Proceedings of the 18<sup>th</sup> Annual Scientific Meeting of the American Pain Society, 1999.
24. Pfaffenrath V, Mauskop A. **Zolmitriptan: reliable relief of migraine symptoms with early onset of action.** *Cephalalgia* 2000, 19(4):370.
25. Mauskop A. **Botulinum toxin in the treatment of chronic daily headaches.** *Cephalalgia* 2000, 19(4):453.
26. Mauskop A, Groszsmann WM, Schmidramsl H. **Petasites hybridus (Butterbur root) extract is effective in the prophylaxis of migraines. Results of a randomized, double-blind trial.** *Headache* 2000;40(5):420.
27. Mauskop A, Basdeo R. **Botulinum toxin A is an effective prophylactic therapy for migraines.** *Cephalalgia* 2000, 20(4):422.
28. Mauskop, A. **Vagus nerve stimulation for refractory migraine.** *Neurology* 2001;56(Suppl 3) A65.
29. Mauskop A. **Long-Term Use of Botulinum Toxin Type A in the Treatment of Headaches.** *Neurology* 2002;58(Suppl 3) A497.
30. Lipton RB, Gobel H, Wilks K, Mauskop A. **Efficacy of Petasites (an Extract from Petasites Rhizome) 50 and 75 mg for Prophylaxis of Migraine: Results of a Randomized, Double-Blind, Placebo-Controlled Study.** *Neurology* 2002;58(Suppl 3) A472.
31. Silberstein SD, Loder E, Elkind A, Mauskop A, Goldstein G, Wasiewski W. **Age-Related Differences in Tolerability and Efficacy Profiles to Zolmitriptan in the Treatment of Migraine Associated with Menses.** *Headache* 2002;42(5):399-400.
32. Mauskop A. **Long-Term Use of Botulinum Toxin Type A (Botox) in the Treatment of Episodic and Chronic Migraine Headaches.** *Headache* 2002;42(5):454-455.
33. Lipton RB, Gobel H, Wilkes K, Mauskop A. **A special extract from Petasites Hybridus Root is effective as a Preventive Treatment for Migraine.** *Headache* 2002;42(5):406-407.
34. Dodick DW, Mauskop A, Elkind AH, et al. **Botulinum Toxin Type A for the Prophylaxis of Chronic Daily Headache: Subgroup Analysis of Patients Not Receiving Other Prophylactic Medications (A Randomized Double-Blind, Placebo-Controlled Study).** *Neurology* 2005;64 (suppl 1):A422.
35. Rapoport AM, Mauskop A, Schwalen S, et al. **Long-term Effectiveness of Topiramate for Migraine Prevention: Analyses of Open-Label, Extension Phase Data from Two Pivotal Studies.** *Neurology* 2005;64(suppl 1):A336-337.

36. Cady R, Martin V, Mauskop A, Rodgers A, Hustad CM, Ramsey, KE, Skobieranda F. **Efficacy of rizatriptan administered in an early intervention model: the rizatriptan TAME (Treat A Migraine Early) Study.** *Cephalalgia*, 2005, 25(10):926.
37. Cady R, Martin V, Mauskop A, Rodgers A, Hustad CM, Ramsey, KE, Skobieranda F. **Impact of rizatriptan on functional disability in an early intervention model: results from the TAME Study.** *Cephalalgia* 2005;25(10):931.
38. Cady R, Martin V, Mauskop A, Ramsey, KE, Rodgers A, Hustad CM, Skobieranda F. **Symptoms of cutaneous sensitivity pretreatment and posttreatment: results from the rizatriptan TAME study.** *Cephalalgia* 2005;25(10):860.
39. Mauskop A, Saper J, Dodick D, et al., **Program to Assess Headache Treatment Strategies: Baseline and Preliminary Results from an Observational Study of Botulinum Toxin Type A Prophylactic Headache Treatment.** *Neurology* 2006.
40. Smith T, Blumenthal H, Diamond M, Mauskop A, Ames M, McDonald SA, Lener S, Burch S. **Long-term clinical and patient-reported benefits of a fixed single-tablet formulation of sumatriptan with RT Technology™ and naproxen sodium in a moderate/severe treatment paradigm.** *Headache*, 2006;46(5)865-866.
41. Martin V, Cady R, Mauskop A, Seidman LS, Rodgers A, Hustad CM, Skobieranda F. **Efficacy of rizatriptan for Menstrual Migraine in the TAME (Treat A Migraine Early) Studies.** *Headache*, 2006;46(5):843.
42. Silberstein SD, Mauskop A, Dodick D, et al. **Program to Assess Headache Treatment Strategies: An Observational Study of Botulinum Toxin Type A in the Preventive Treatment of Headache.** *Headache*, 2006;46(5)846-847.
43. Martin V, Cady R, Mauskop A, Seidman LS, Rodgers A, Skobieranda F. **Efficacy of rizatriptan for Menstrual Migraine in the Treat A Migraine Early (TAME) Studies.** *Obstet Gynecol* 2006;107 (4 suppl):75.
44. Mauskop A: **Migralex – A New OTC Medication for Acute Therapy of Migraine. An Open-Label Trial.** *Headache* 2008;48(S1):S45.

## BOOKS

1. Mauskop A, Abrams-Brill M: **The Headache Alternative: A Neurologist's Guide to Drug-Free Relief.** Dell, New York, 1997.
2. Mauskop A, Fox B, **What Your Doctor May Not Tell You About Migraines.** Warner Books, New York, 2001.
3. Mauskop A. **Migraine and Headaches.** Oxford University Press. New York, 2009..

## CHAPTERS & REVIEWS

1. Mauskop A, Foley KM: **Control of pain.** In: *Orthopedic Management of Metastatic Bone Disease.* (ed. Harrington) C. V. Mosby, 1987.
2. Mauskop A: **Pain syndromes in neurology.** Book Review. *Journal of Pain and Symptom Management* 7(7):434,1992.
3. Mauskop A: **Trigeminal neuralgia.** Book Review. *Journal of Pain and Symptom Management* 7(6):377,1992.
4. Mauskop A: **Trigeminal neuralgia.** *Journal of Pain and Symptom Management.* 8(3):148-154,1993.

5. Mauskop A: **Pain**. In: *Conn's Current Therapy* 1994. (ed. R.E. Rakel) W.B. Saunders Company, 1994.
6. Mauskop A: **Pain**. In: *Conn's Current Therapy* 1995. (ed. R.E. Rakel) W.B. Saunders Company, 1995.
7. Mauskop A: **Headaches**. In: *A Practical Approach to Pain Management* (eds. Lefkowitz and Leibowitz) Little, Brown and Company, 1996.
8. Mauskop A: **Painful neuropathies**. In: *A Practical Approach to Pain Management*. (eds. Lefkowitz and Leibowitz) Little, Brown & Company, 1996.
9. Mauskop A, Golstein J: **The role of 5HT<sup>1D</sup>-receptor agonists and magnesium in the treatment of migraine headaches**. *Current Review of Pain*, 1997;1 (3).
10. Mauskop A: **Migraine headache**. In: *Neurology Practice Guidelines* (eds., Lechtenberg and Schutta) Marcel Dekker, NY 1997.
11. Mauskop A, Altura BT, Cracco RQ, Altura BM: **Intravenous magnesium sulfate aborts migraine headache attacks in patients with low serum ionized magnesium levels**. In: *Advances in Magnesium Research*:1, R. Smetana, ed. London, John Libbey, 1997, 238-242.
12. Mauskop A. **Head Pain**. In: *The management of pain*. Ashburn MA and Rice LJ, eds. Churchill Livingstone, 1997.
13. Mauskop A, Altura BM: **Magnesium for migraine: Rationale for use and therapeutic potential**. *CNS Drugs*, 1998;9:185-190.
14. Mauskop A, Altura BM.: **Role of magnesium in the pathogenesis and treatment of migraines**. *Clinical Neuroscience* 1998;5:24-28.
15. Mauskop A: Guest Editor. **Neurobiology of migraine**. *Clinical Neuroscience* 1998;Vol.5.
16. Mauskop A: **Pain**. In: *Conn's Current Therapy* 1998 (ed.R.E.Rakel)W.B. Saunders Company, 1998.
17. Mauskop A, Leybel B: **Headache in sports**. In: *Sports Neurology* (ed. B. Jordan) Lippincott, 1998.
18. Mauskop A: **Complementary modes of therapy for headaches**. *Journal of the American Osteopathic Association*, 1998;98(6, suppl):S16-S19.
19. Mauskop A: **Headaches**. In: *Conn's Current Therapy* 1999. (ed. R.E.Rakel), W.B. Saunders Company, 1999.
20. Mauskop A: **Evidence linking magnesium deficiency to migraines**. Editorial. *Cephalalgia* 1999;19:766-767.
21. Mauskop A: **Alternative therapies in headache: Is there a role?** In: *Medical Clinics of North America* 85 (4): 1077-1084, 2001.
22. Mauskop A: **The Use of Botulinum Toxin in the Treatment of Headaches**. *Current Pain and Headache Reports*. 2002;6(4):320-323.
23. Mauskop A: **Pain**. In: *Conn's Current Therapy* 2003 (eds. Rakel and E.T. Bope), W.B. Saunders Company.
24. Holroyd KA and Mauskop A: **Complementary and alternative treatments**. *Neurology* 2003; 60(Suppl 2):S58-62.
25. Mauskop A: **Pain**. In: *Conn's Current Therapy* 2004 (eds. R.E.Rakel and E.T. Bope)W.B. Saunders Company.
26. Mauskop A: **Headache**. In: *Integrating Complementary Therapies into Neurology*. (ed. Barry S. Oken), 2004, The Parthenon Publishing Group.

27. Mauskop A: **Acute Treatment of Migraine Headaches**. In: *Seminars in Pain Medicine*. 2004; Vol. 2, No. 2:72-75.
28. Mauskop A: **The Use of Botulinum Toxin in the Treatment of Headaches**. *Pain Physician*. 2004;7:377-387.
29. Mauskop A: **Trigeminal Neuralgia**. In: *Conn's Current Therapy* 2006 (eds. R.E.Rakel and E.T. Bope)W.B. Saunders Company
30. Samton JB and Mauskop A. **The treatment of headaches with Botulinum Toxin**. *Expert Review of Neurotherapeutics* March 2006, Vol. 6, No. 3, Pages 313-322.
31. Mauskop A. **Complementary and alternative treatments for migraine**. *Drug Dev Res* 2007;68:424-427.
32. [Sun-Edelstein C](#), [Mauskop A](#). **Complementary and alternative approaches to the treatment of tension-type headache**. *Curr Pain Headache Rep*. 2008 Dec;12(6):447-50.
33. Sun-Edelstein C and Mauskop A. **Migraine headaches. Food Triggers and Nutrient Therapies**. In: *Food and Nutrients in Disease Management*. (ed. Ingrid Kohlstadt), 2009, CRC Press.
34. Sun-Edelstein C and Mauskop A. **Role of magnesium in the pathogenesis and treatment of migraine**. *Expert Review of Neurotherapeutics*. 2009;9(3):369-379.
35. Sun-Edelstein C and Mauskop A. **Foods and supplements in the management of migraine headaches**. *Clin J Pain*. 2009;25(5):446-52.

#### OTHER PUBLICATIONS

1. Coyle N, Mauskop A, Maggard J, Foley KM: **Continuous subcutaneous infusions of opiates in cancer patients with pain**. *Oncology Nursing Forum*. 13:53-57,1986.
2. Mauskop A: **Treatment of headaches**. *Resident Reporter*, Medical Society of County of Kings, September, 1988.
4. Mauskop A: **How to treat headaches**. *The West Side Spirit*, October 24,1988.
5. Mauskop A: **Treatment of headaches with acupuncture**. *National Headache Foundation Newsletter*, 1988.
6. Mauskop A: **Acupuncture for addicts**. Letter to the Editor, *The New York Times*, December 24,1988.
7. Mauskop A: **Headaches in children**. *National Headache Foundation Newsletter*, 1989.
8. Mauskop A: **Biofeedback and headaches**. *National Headache Foundation Newsletter*, 1991.
9. Mauskop A: **Headaches and children: A reply to "An urban primary school health program"**. *NY State Med J* 92:24,1992.
10. Mauskop A: **Relief from postpartum headaches**. *New York Family*. May 1992.
11. Mauskop A: **Guest editor, special section on headache**. *Journal of Pain and Symptom Management*. 8(2):72,1993.
12. Mauskop A: **Oral laser treatment**. *National Headache Foundation Newsletter*, 1993.
13. Mauskop A: **Magnesium and headaches**. *National Headache Foundation Newsletter*, 1993.
14. Mauskop A: **Headaches and Epilepsy**. *Epilepsy Institute Newsletter*, 1993.
15. Mauskop A: **Oral Laser Treatment**. Letter to the Editor. *Headache Quarterly* 1994.
16. Mauskop A: **Treatment of Pain Should be Discussed**. Letter to the Editor. *The New York Times*, May 30, 1994.

17. Mauskop A: **Magnesium and headaches: An update.** *National Headache Foundation Newsletter*, 1996.
18. Mauskop A: **Ethics in China.** Letter to the Editor. *The New York Times*, April 7, 2000.
19. Mauskop A: **A Call to Action?** Letter to the Editor. *The New York Times*, December 13, 2000.
20. Mauskop A: **Clinical features of withdrawal headache following overuse of triptans and other headache drugs.** Letter to the Editor. *Neurology* 2002;58:1443.
21. Mauskop A: **The Role of Alternative Therapies in Headache.** *National Headache Foundation Newsletter*, Nov/Dec, 2002.
22. Mauskop A. **Re: Hord ED et al. The effect of vagus nerve stimulation on migraines.** *J Pain.* 2003;4(9):530-4.
23. Mauskop A: **Simplified Butalbital Withdrawal Protocol.** Letter to the Editor. *Headache* 2004, 44(3):290-291.
24. Mauskop A: **Misery of Migraine.** Letter to the Editor. *The New York Times*, August 15, 2006.
25. Mauskop A: **Case Studies in Headache: Basilar Migraine.** *NHF Head Lines*, Number 152, September/October 2006.
26. Mauskop A: **Botulinum toxin in headache treatment: the end of the road?** *Cephalalgia.* 2007;27:468.
27. Mauskop A., Mathew N. **Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain** (An evidence-based review): Report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology. Letter to the Editor. *Neurology* 2009, 72:1367-1369.

## CLINICAL TRIALS

1. An open label long-term trial evaluating the safety of BMS-1 80048 150 mg in the treatment of patients with migraine headache with or without aura.
2. A randomized, triple-blind, placebo-controlled, parallel groups, outpatient study to examine the safety, tolerability, and efficacy of MK-0462 for the acute treatment of migraine.
3. A multicenter, double-blind, randomized study to evaluate the impact of product education on patient satisfaction with Stadol NS nasal spray for treatment of acute migraine headache pain.
4. A multicenter, double-blind, placebo-controlled, randomized trial of intranasal dihydroergotamine.
5. A randomized, double-blind, placebo controlled, parallel group, multi-center, single dose, dose-range-finding study of VML-251 in the acute treatment of migraine.
6. Intravenous magnesium sulfate in the treatment of acute migraine attacks in patients with low and normal ionized magnesium levels. Principal investigator.
7. Oral magnesium supplementation in the treatment of menstrual migraines and PMS syndrome. A pilot study. Principal investigator.
8. A multicenter, long term study to maximize migraine relief with 311C90 (MAXIMM).
9. A multi-center trial of a novel 5-HT<sub>1B/1D</sub> drug in the treatment of migraine headaches that failed to respond to sumatriptan.

10. A multicenter, double-blind, placebo-controlled, randomized trial of zolmitriptan for the treatment of menstrual-associated migraine headaches.
11. A phase II, randomized, placebo-controlled study to assess the safety and efficacy of galantamine in patients with the diagnosis of chronic fatigue syndrome.
12. Rizatriptan vs. sumatriptan preference study.
13. A multi-center, double-blind, placebo-controlled, randomized trial an open-label long-term tolerability trial of zolmitriptan for the acute treatment of migraine headaches in adolescent subjects.
14. A multi-center, double-blind, placebo-controlled, randomized parallel study to assess the safety and efficacy of BOTOX<sup>®</sup> (botulinum toxin type A) purified neurotoxin complex injected into bilateral pericranial muscles for the prophylactic treatment of chronic tension headaches.
15. A randomized, multi-center, double-blind, placebo-controlled, parallel-group clinical study evaluating the efficacy and safety of two different doses of petasites extract (Petadolex<sup>®</sup>) in the prophylaxis of migraines.
16. A multi-center, double-blind, placebo-controlled, randomized parallel study to assess the safety and efficacy of BOTOX<sup>®</sup> (botulinum toxin type A) purified neurotoxin complex injected into bilateral pericranial muscles for the prophylactic treatment of migraine headaches.
17. Double-blind, randomized, placebo-controlled, crossover trial of intravenous magnesium sulfate for the prevention of menstrual migraine.
18. Efficacy of a five-component migraine formula as prophylactic for migraine. A double blind, placebo-controlled randomized trial. Principal investigator
19. A randomized, double-blind, placebo-controlled, parallel group, single attack evaluation of a triptan versus placebo during a migraine headache at first sign of pain.
20. A randomized, double-blind, placebo-controlled, parallel groups, outpatient study to examine the safety, tolerability and efficacy of rizatriptan 5 mg PO for the acute treatment of migraine headaches in adolescents.
21. A multi-center, double-blind, randomized, placebo-controlled, parallel group study of BOTOX<sup>®</sup> (botulinum toxin type A) purified neurotoxin complex for the prophylactic treatment of migraine headaches in the episodic migraine population.
22. A multi-center, double-blind, randomized, placebo-controlled, parallel group study of BOTOX<sup>®</sup> (botulinum toxin type A) purified neurotoxin complex for the prophylactic treatment of migraine headaches in the chronic headache population.
23. A randomized, double-blind, placebo-controlled, parallel-group dose-response study to evaluate the efficacy and safety of topiramate in the prophylaxis of migraines.
24. A rapidly-acting NSAID vs a triptan in acute migraine: Double-blind, placebo-controlled in-patient study.
25. A phase III, double-blind, randomized, placebo-controlled, parallel-group, multicenter evaluation of civamide (zucapsaicin) nasal solution in the treatment of episodic cluster headache
26. Vagus nerve stimulation in the treatment of refractory migraines.
27. Phase II, double-blind, randomized, placebo-controlled, in-patient trial of an investigational abortive migraine drug.
28. Escitalopram (Lexapro<sup>®</sup>) effects on quality of life study.

29. A multi-center, double-blind, randomized, placebo-controlled study of eletriptan (Relpax<sup>®</sup>) versus placebo in early treatment of migraine.
30. A multicenter, randomized, placebo-controlled, double-blind, parallel-group, trial to evaluate early efficacy and tolerability of zolmitriptan (ZOMIG<sup>®</sup>) nasal spray in the acute treatment of adult subjects with migraine.
31. An open-label trial of levetiracetam (Keppra<sup>®</sup>) in the prophylactic treatment of migraine headaches.
32. A multi-center, randomized, double-blind comparison of the efficacy and safety of Aricept<sup>®</sup> versus Inderal LA<sup>®</sup> in migraine prophylaxis.
33. Human clinical investigation of a homeopathic drug for migraine headache. A double-blind placebo-controlled trial.
34. A randomized, double-blind, placebo-controlled, parallel-group, single-attack study to evaluate the onset of efficacy of a new formulation of sumatriptan tablets 50 mg and 100 mg in the acute treatment of migraine.
35. Program to Assess Treatment Strategies: A Botox Observational Program.
36. A Multicenter, Double-blind, Randomized, Parallel, Placebo-Controlled Study to Examine the Efficacy of Rizatriptan 10-mg Tablet Administered Early During a Migraine Attack While the Pain is Mild.
37. A Double-Blind, Multicenter, Randomized, Placebo-Controlled Single Dose Study to Evaluate the Safety and Efficacy of Trexima in the Acute Treatment of Migraine Headaches.
38. A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Single-Attack Evaluation of the Efficacy and Tolerability of Trexima Tablets vs Placebo when Administered During the Mild Pain Phase of a Migraine.
39. A double-blind, placebo-controlled, parallel-group study, with an open-label extension phase to assess the efficacy, tolerability and safety of oral frovatriptan in the prevention of menstrually-related migraine headaches in a “difficult to treat” population.
40. An Open-Label, Repeat Dose Study of the Safety of Combo Formulation in the Treatment of Multiple Episodes of Acute Migraine over 12 Months.
41. A multicenter, double-blind, randomized, parallel-group, placebo-controlled study to evaluate the efficacy and tolerability of rizatriptan 10-mg tablet for the treatment of menstrual migraine.
42. Botulinum neurotoxin type A for treatment of chronic migraine: the PREEMPT trial.

Pharmaceutical sponsors of the above trials include: **Allergan, AstraZeneca, Bristol-Myers-Squibb, Cyberonics, Eisai, GlaxoSmithKline, Merck, Novartis, Ortho-McNeil, Pfizer, Pozen, Royal Numico, Vanguard, Weber & Weber, Winston Laboratories, Wyeth.**